Davunetide in patients with progressive supranuclear palsy: A randomised, double-blind, placebo-controlled phase 2/3 trial

The Lancet Neurology

Volumn 13, Issue 7, 2014, Pages 676-685

  Boxer, Adam L ^a   Lang, Anthony E ^b   Grossman, Murray ^c   Knopman, David S ^d   Miller, Bruce L ^a   Schneider, Lon S ^e   Doody, Rachelle S ^f   Lees, Andrew ^g   Golbe, Lawrence I ^h   Williams, David R ⁱ   Corvol, Jean Cristophe ^j,k   Ludolph, Albert ^l   Burn, David ^m   Lorenzl, Stefan ⁿ   Litvan, Irene ^o   Roberson, Erik D ^p   Höglinger, Günter U ^q   Koestler, Mary ^a   Jack, Clifford R ^d   Van Deerlin, Viviana ^r   Randolph, Christopher ^s   Lobach, Iryna V ^a   Heuer, Hilary W ^a   Gozes, Illana ^t   Parker, Lesley ^u   Whitaker, Steve ^v   Hirman, Joe ^w   Stewart, Alistair J ^x   Gold, Michael ^y   Morimoto, Bruce H ^z   more..

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d MAYO CLINIC   (United States)

^e UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^f BAYLOR COLLEGE OF MEDICINE   (United States)

^g UNIVERSITY COLLEGE LONDON   (United Kingdom)

^h ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

ⁱ MONASH UNIVERSITY   (Australia)

^j ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^k PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^l UNIVERSITY HOSPITAL ULM   (Germany)

^m NEWCASTLE UNIVERSITY   (United Kingdom)

ⁿ LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^o UNIVERSITY OF CALIFORNIA   (United States)

^p University of Alabama at Birmingham   (United States)

^q TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^r UNIVERSITY OF PENNSYLVANIA   (United States)

^s LOYOLA UNIVERSITY CHICAGO   (United States)

^t TEL AVIV UNIVERSITY   (Israel)

^u Tekmira Pharmaceuticals Corporation   (Canada)

^v OMEROS CORPORATION   (United States)

^w Pacific Northwest Statistical Consulting   (United States)

^x Product Development   (Canada)

^y UCB PHARMA   (Belgium)

^z CELERION   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

DAVUNETIDE; LEVODOPA; NOSE SPRAY; PLACEBO; RASAGILINE; UBIDECARENONE;

AGED; APPLICATION SITE INFECTION; ARTICLE; AUSTRALIA; CONNECTIVE TISSUE DISEASE; CONSTIPATION; CONTROLLED STUDY; CONTUSION; COUGHING; DAILY LIFE ACTIVITY; DEPRESSION; DISEASE EXACERBATION; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DYSPHAGIA; EPISTAXIS; EYE DISEASE; FALLING; FEMALE; FOLLOW UP; FRANCE; GASTROINTESTINAL DISEASE; GERMANY; HISTORY; HUMAN; INFESTATION; INSOMNIA; INTENTION TO TREAT ANALYSIS; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; MEDIASTINUM DISEASE; MENTAL DISEASE; METABOLIC DISORDER; MULTICENTER STUDY; MUSCULOSKELETAL DISEASE; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; NASAL DISCOMFORT; NEUROLOGIC DISEASE; NEUROPROTECTION; NOSE DISEASE; NOSE MUCOSA; NOSE OBSTRUCTION; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; NUTRITIONAL DISORDER; OUTCOME ASSESSMENT; PARKINSON DISEASE; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSIVE SUPRANUCLEAR PALSY; PROGRESSIVE SUPRANUCLEAR PALSY RATING SCALE; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; RESPIRATORY TRACT DISEASE; RHINOPHARYNGITIS; RHINORRHEA; SCHWAB AND ENGLAND ACTIVITIES OF DAILY LIVING SCALE; SIDE EFFECT; SKIN DISEASE; SKIN INJURY; THORAX DISEASE; TREATMENT RESPONSE; UNITED KINGDOM; UNITED STATES; URINARY TRACT INFECTION; VASCULAR DISEASE;

AGED; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; OLIGOPEPTIDES; SUPRANUCLEAR PALSY, PROGRESSIVE; TREATMENT OUTCOME;

EID: 84902545124     PISSN: 14744422     EISSN: 14744465     Source Type: Journal    
DOI: 10.1016/S1474-4422(14)70088-2     Document Type: Article

References (43)

1. Stamelou M, de Silva R, Arias-Carrion O, et al. Rational therapeutic approaches to progressive supranuclear palsy. Brain 2010, 133:1578-1590.
2. Steele JC, Richardson JC, Olszewski J Progressive Supranuclear Palsy. A heterogeneous degeneration involving the brain stem, basal ganglia and cerebellum with vertical gaze and pseudobulbar palsy, nuchal dystonia and dementia. Arch Neurol 1964, 10:333-359.
3. Williams DR, Lees AJ Progressive supranuclear palsy: clinicopathological concepts and diagnostic challenges. Lancet Neurol 2009, 8:270-279.
4. Nath U, Ben-Shlomo Y, Thomson RG, et al. The prevalence of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) in the UK. Brain 2001, 124:1438-1449.
5. Hoglinger GU, Melhem NM, Dickson DW, et al. Identification of common variants influencing risk of the tauopathy progressive supranuclear palsy. Nat Genet 2011, 43:699-705.
6. Morimoto BH, Schmechel D, Hirman J, Blackwell A, Keith J, Gold M A double-blind, placebo-controlled, ascending-dose, randomized study to evaluate the safety, tolerability and effects on cognition of AL-108 after 12 weeks of intranasal administration in subjects with mild cognitive impairment. Dement Geriatr Cogn Disord 2013, 35:322-336.
7. Reed LA, Wszolek ZK, Hutton M Phenotypic correlations in FTDP-17. Neurobiol Aging 2001, 22:89-107.
8. Dickson DW, Ahmed Z, Algom AA, Tsuboi Y, Josephs KA Neuropathology of variants of progressive supranuclear palsy. Curr Opin Neurol 2010, 23:394-400.
9. Boxer AL, Gold M, Huey E, et al. The advantages of frontotemporal degeneration drug development (part 2 of frontotemporal degeneration: the next therapeutic frontier). Alzheimers Dement 2013, 9:189-198.
10. Shiryaev N, Jouroukhin Y, Giladi E, et al. NAP protects memory, increases soluble tau and reduces tau hyperphosphorylation in a tauopathy model. Neurobiol Dis 2009, 34:381-388.
11. Brown RG, Lacomblez L, Landwehrmeyer BG, et al. Cognitive impairment in patients with multiple system atrophy and progressive supranuclear palsy. Brain 2010, 133:2382-2393.
12. Bensimon G, Ludolph A, Agid Y, Vidailhet M, Payan C, Leigh PN Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study. Brain 2009, 132:156-171.
13. Golbe LI, Ohman-Strickland PA A clinical rating scale for progressive supranuclear palsy. Brain 2007, 130:1552-1565.
14. Schwab R, England A Projecton technique for evaluating surgery in Parkinson's disease. Third Symposium on Parkinson's Disease Research 1969, ES Livingstone, Edinburgh, Scotland. F. Gillingham, M. Donaldson (Eds.).
15. Schneider LS, Olin JT, Doody RS, et al. Validity and reliability of the Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord 1997, 11(suppl 2):S22-S32.
16. Whitwell JL, Jack CR, Parisi JE, et al. Rates of cerebral atrophy differ in different degenerative pathologies. Brain 2007, 130:1148-1158.
17. Payan CA, Viallet F, Landwehrmeyer BG, et al. Disease severity and progression in progressive supranuclear palsy and multiple system atrophy: validation of the NNIPPS-Parkinson Plus Scale. PLoS One 2011, 6:e22293.
18. Randolph C, Tierney MC, Mohr E, Chase TN The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS): preliminary clinical validity. J Clin Exp Neuropsychol 1998, 20:310-319.
19. Yesavage JA, Brink TL, Rolse TL, et al. Development and validity of a Geriatric Depression Scale: a preliminary report. J Psychiatric Res 1983, 17:37-49.
20. Scherling CS, Hall T, Berisha F, et al. Cerebrospinal fluid neurofilament concentration reflects disease severity in frontotemporal degeneration. Ann Neurol 2014, 75:116-126.
21. Lachin JM Worst-rank score analysis with informatively missing observations in clinical trials. Control Clin Trials 1999, 20:408-422.
22. LaVange LM, Durham TA, Koch GG Randomization-based nonparametric methods for the analysis of multicentre trials. Stat Methods Med Res 2005, 14:281-301.
23. Tolosa E, Litvan I, Hoglinger GU, et al. A phase 2 trial of the GSK-3 inhibitor tideglusib in progressive supranuclear palsy. Mov Disord 2014, 29:470-478. TAUROS Investigators.
24. Stamelou M, Reuss A, Pilatus U, et al. Short-term effects of coenzyme Q10 in progressive supranuclear palsy: a randomized, placebo-controlled trial. Mov Disord 2008, 23:942-999.
25. Litvan I, Phipps M, Pharr VL, Hallett M, Grafman J, Salazar A Randomized placebo-controlled trial of donepezil in patients with progressive supranuclear palsy. Neurology 2001, 57:467-473.
26. Poujois A, Vidailhet M, Trocello JM, Bourdain F, Gaymard B, Rivaud-Pechoux S Effect of gabapentin on oculomotor control and parkinsonism in patients with progressive supranuclear palsy. Eur J Neurol 2007, 14:1060-1062.
27. Daniele A, Moro E, Bentivoglio AR Zolpidem in progressive supranuclear palsy. New Engl J Med 1999, 341:543-544.
28. Frattali CM, Sonies BC, Chi-Fishman G, Litvan I Effects of physostigmine on swallowing and oral motor functions in patients with progressive supranuclear palsy: A pilot study. Dysphagia 1999, 14:165-168.
29. Rascol O, Sieradzan K, Peyro-Saint-Paul H, et al. Efaroxan, an alpha-2 antagonist, in the treatment of progressive supranuclear palsy. Mov Disord 1998, 13:673-676.
30. Ghika J, Tennis M, Hoffman E, Schoenfeld D, Growdon J Idazoxan treatment in progressive supranuclear palsy. Neurology 1991, 41:986-991.
31. Litvan I, Gomez C, Atack JR, Gillespie M, Kask AM, Mouradian MM, et al. Physostigmine treatment of progressive supranuclear palsy. Ann Neurol 1989, 26:404-407.
32. Foster NL, Aldrich MS, Bluemlein L, White RF, Berent S Failure of cholinergic agonist RS-86 to improve cognition and movement in PSP despite effects on sleep. Neurology 1989, 39(2 pt 1):257-261.
33. Newman GC Treatment of progressive supranuclear palsy with tricyclic antidepressants. Neurology 1985, 35:1189-1193.
34. Jankovic J Controlled trial of pergolide mesylate in Parkinson's disease and progressive supranuclear palsy. Neurology 1983, 33:505-507.
35. Höglinger GU, Huppertz HJ, Wagenpfeil S, et al. Tideglusib reduces progression of brain atrophy in progressive supranuclear palsy in a randomized trial. Mov Disord 2014, 29:479-487.
36. Fagan AM, Shaw LM, Xiong C, et al. Comparison of analytical platforms for cerebrospinal fluid measures of beta-amyloid 1-42, total tau, and p-tau181 for identifying Alzheimer disease amyloid plaque pathology. Arch Neurol 2011, 68:1137-1144.
37. Hall S, Ohrfelt A, Constantinescu R, et al. Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders. Arch Neurol 2012, 69:1445-1452.
38. Gunnarsson M, Malmestrom C, Axelsson M, et al. Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumab. Ann Neurol 2011, 69:83-89.
39. Blennow K, Zetterberg H, Rinne JO, et al. Effect of immunotherapy with bapineuzumab on cerebrospinal fluid biomarker levels in patients with mild to moderate Alzheimer disease. Arch Neurol 2012, 69:1002-1010.
40. Kester MI, Scheffer PG, Koel-Simmelink MJ, et al. Serial CSF sampling in Alzheimer's disease: specific versus non-specific markers. Neurobiol Aging 2012, 33:1591-1598.
41. Paviour DC, Price SL, Jahanshahi M, Lees AJ, Fox NC Longitudinal MRI in progressive supranuclear palsy and multiple system atrophy: rates and regions of atrophy. Brain 2006, 129:1040-1049.
42. Josephs KA, Xia R, Mandrekar J, et al. Modeling trajectories of regional volume loss in progressive supranuclear palsy. Mov Disord 2013, 28:1117-1124.
43. Maruyama M, Shimada H, Suhara T, et al. Imaging of tau pathology in a tauopathy mouse model and in Alzheimer patients compared to normal controls. Neuron 2013, 79:1094-1108.